Atherosclerosis is a disease of the arterial wall, with increasing wall thickness representing an early event in the progression of the disease. It has been suggested that iron overload, as assessed by increased serum ferritin concentration, may be a risk factor for atherosclerosis.
arteries, and thickened common carotid IMT is also an indicator of early-phase coronary atherosclerosis. 2) There are several risk factors whose association with atherosclerosis is well established, including age, gender, lipid disorders, smoking, hypertension, diabetes mellitus, obesity, and lifestyle.
3) Yet, about 25 percent of cardiovascular disease (CVD) deaths in men and 15 percent in women occur in persons with lower multivariate Framingham Study risk scores in the lowest two quintiles according to standard risk factors. 4) It has been suggested that about half of atherosclerosis cases cannot be attributed to standard risk factors. 5) This fact has recently stimulated a call for investigation of new risk factors. 6) Anemia is a major cause of morbidity and mortality in hemodialysis (HD) patients. Optimal anemia management, usually requiring erythropoietin (EPO) therapy, improves the life of end-stage renal disease patients. 7) Functional iron deficiency clearly limits the ability of EPO to support erythropoiesis, therefore, avoiding functional iron deficiency has cost benefits associated with reduced EPO dose requirements. 8) The National Kidney Foundation -Dialysis Outcomes Quality Initiative (NKF-DOQI) Guidelines for Anemia Management recommend that intravenous iron be used to prevent iron deficiency and support erythropoiesis. 9) However, use of parenteral iron can produce iron overload, has been linked with tissue deposition of iron, and potentially can increase oxidative stress, thereby inducing cardiac disease.
7) The purpose of this study was to investigate the relationship between the influence of intravenous (IV) iron therapy and ferritin levels and carotid intima media thickness (IMT) as assessed by ultrasound in a group of dialysis patients.
METHODS
We studied 60 ESRD patients (age, 51 ± 14) from the hospital dialysis unit of Gazi University Medical Center (Ankara, Turkey). The study protocol was approved by Gazi University, and the patients were informed of the purpose of the study before giving their voluntary consent. Patients who had been on dialysis three times weekly for at least 24 months (44.9 ± 26.7) were included. Seventy percent were male, 30% female, 20% had insulin dependent diabetes mellitus, and 68% were being treated with antihypertensive drugs. The patients were divided into two groups according to carotid intima-media thickness (C-IMT) obtained by ultrasound. Group I patients had an IMT ≥ 0.75 mm or abnormality of the arterial wall (eg, atherosclerotic plaque), group II patients had an C-IMT and no plaque of the arterial wall had an C-IMT < 0.75 mm. Intima-medial thickening is an abnormality of the arterial wall and a value of 0.75 mm was considered to be a critical threshold beyond which plaque formation is accelerated. Mean age was 55 ± 13 in group I (n = 43) and 41 ± 13 in group II (n = 17) (P < 0.05). The parameters used to assess predialysis were serum creatinine, urea, calcium, phosphorus, hemoglobin, albumin, iron, ferritin, uric acid, parathyroid hormone (PTH), C-reactive protein, and lipids. C-reactive protein was measured using a high-sensitivity latex particle turbidimetric assay (COBAS INTEGRA 400, Roche Diagnostics, Turkey). Other standard hematological and biochemical laboratory tests were measured routinely. Patients who had high cholesterol levels and had received lipid-lowering agents or diet therapy were considered to have hypercholesterolemia. Ferritin, hs-CRP, and PTH levels were measured every six months and their medium values taken. These parameters were only measured every six months because the health insurance of the patients did not pay for more measurements. The other biochemical parameters were measured every month and their medium values were taken.
Patients with acute or chronic infections or chronic systemic disease, active liver disease, acute myocardial infarction, or cerebrovascular disease were excluded. Patients were dialyzed with hemophane membranes matched to body surface area (1.2 -2.0 m 2 ) and bicarbonate-buffered dialysate. Intravenous iron sucrose treatment in conjuction with erythropoietin was performed according to the NKF/DOQI guidelines (Hgb levels 11 to 12 g/dL, Hct 33% to 36%). Intravenous iron sucrose was prescribed when the transferrin saturation was < 20% and/ or serum ferritin was < 100 pg/mL. The iron therapy was interrupted when the ferritin levels were ≥ 800 pg/mL, and/or the transferrin saturation was ≥ 50%. Iron sucrose was diluted in 100 mL 0.9% sodium chloride for infusion and administered in the last 30 minutes of the hemodialysis session. After the loading dose, 50 to 100 mg of iron therapy was given weekly.
Sonographic examination of the bilateral carotid arteries was performed in the supine position by a single examiner who was blinded to the clinical and biochemical data. All patients were evaluated by high-resolution ultrasound using a Logic 9 (GE Corp. Waukesha, WI) system and a 7.5 MHz linear array transducer. Intima-media thickness was described as the distance from the leading edge of the lumen-intima interface to the media-adventitia interface of the carotid artery. Intima-media thickness of the right and left common carotid arteries was measured within the 1 cm segment proximal to the dilatation of the carotid bulb, at sagittal planes. The carotid plaques were excluded while measuring intima-media thickness. All measurements were made manually on still images obtained during sonographic scanning.
During the screening visit, weight and height were measured with the patients in light clothing without shoes. Body mass index was calculated by dividing weight by the square of height. The presence or absence of coronary artery disease (CAD) was recorded. Subjects were considered to have hyperten-sion if a history of hypertension requiring treatment was recorded. A smoking habit was defined as current smoking and dialysis durations were recorded. Statistical analysis: Results are expressed as the mean ± SD. Comparisons between groups were performed using the unpaired Student's t test. Correlations were evaluated using Pearson's correlation test. Significant risk factors were evaluated using logistic regression and multivariate regression analysis. Differences were considered significant at P < 0.05. Statistical analyses were performed using SPSS 9.0 software.
RESULTS
Demographic and clinical data, IMT measurements, and biochemical characteristics are presented in Table I . The incidence of diabetes mellitus was slightly greater in the high vascular risk group (group I), although the difference was not significant (P = 0.081). The duration of dialysis was longer in group I than in group II (P = 0.001). Ferritin levels were higher in group I than in group II (581 ± 303 and 306 ± 224) (P < 0.001). Forty-three patients had received IV 100 mg ferric saccharate once a week or twice a month for the last two years while the other 17 patients had not received IV ferric saccharate. Of the patients who received IV iron therapy, 38 (88%) were in group I and 5 (12%) were in group II. Of the patients who did not receive IV iron therapy, 5 (29%) were in group I and 12 (71%) were in group II (P < 0.001). Age (OR 1.09, 95% CI: 1.02-1.2) (P = 0.01), smoking (OR 7.2, 95% CI: 1.3-39.3) (P = 0.02) and ferritin (OR: 1.5 95% CI: 1.12-2.07) (P = 0.006) were found to be significant risk factors in logistic regression analysis of risk factors associated with group I and group II.
C-IMT was 0.98 ± 0.21 mm in the patients who received IV iron therapy and 0.7 ± 0.17 mm in the patients who did not receive IV iron therapy (P < 0.001). C-IMT was 0.99 ± 0.24 mm in the patients with hypercholesterolemia and 0.84 ± 0.21 mm in the patients without hypercholesterolemia (P = 0.013).
Serum ferritin was significantly correlated with the dose of elemental iron administered during the preceding 24 month period (r = 0.430, P = 0.001) ( Figure  1 ), but it was not correlated with C-reactive protein (r = 0.28, P = 0.831). C-IMT was significantly correlated with age (r = 0.389, P = 0.002), ferritin levels (r = 0.315, P = 0.014), and the total dose of elemental iron (r = 0.471, P = 0.001) (Figures 2 and 3 ). In the multivariate regression analysis, risk factors such as age, ferritin, hypercholesterolemia, intravenous iron dose, and smoking that were Table II . C-IMT was significantly associated with the total dose of elemental iron (r 2 = 0.209, P = 0.001), age (r 2 = 0.293, P = 0.012), and hypercholesterolemia (r 2 = 0.337, P = 0.034).
DISCUSSION
CCA-IMT is considered an early marker of the atherosclerotic process and is currently used to assess the presence and progression of atherosclerosis. 2, 11) Epidemiological studies have showed that increased CCA-IMT was correlated with known cardiovascular risk factors and was associated with an increased prevalence and incidence of cardiovascular disease. 12, 13) Confirming data in the literature, we found that the CCA-IMT increased with age and serum ferritin levels. [14] [15] [16] We also observed that the duration of dialysis was longer in group I patients than in group II patients. Group I patients were older than group II patients and C-IMT increased significantly with age. In our study, there were more diabetic and hypertensive patients in group I than in group II, although the differences were not significant. This statistical finding could provide a rational explanation for our observation that was caused by the relatively small number of patients (see Table II ).
There is increasing epidemiological evidence concerning the role of iron in atherosclerosis and ischemic heart disease. Experimental models show that increased tissue iron amplifies free radical-mediated tissue damage. This tissue injury leads to the production of superoxide radicals which can reduce ferric ion to ferrous ion and generate free radicals. 7) In 1981, Sullivan first proposed the socalled "iron hypothesis" suggesting that the regular menstrual loss of iron, rather than other effects of estrogen, protects women against CVD. 17) Iron is an essential metal involved in a wide spectrum of physiological functions in the body, such as oxygen transport and enzymatic reactions. Nevertheless, excess iron can be dangerous because it promotes the generation of free radicals which subsequently lead to tissue damage. We found that ferritin levels were higher in group I than in group II. Our results show that the annual dose of intravenous iron was significantly correlated with serum ferritin and C-IMT. This association was independent of serum Creactive protein, which was used as a marker of systemic inflammation.
Oxidative modification of low-density lipoprotein (LDL) cholesterol appears to be one of the pivotal steps in atherogenesis. 19) Native LDL cholesterol, whose serum levels correlate well with CHD risk, has a weak atherogenic effect. 19, 20) Oxidized LDL cholesterol has several biological effects that may contribute to the progression of atherosclerotic lesions, such as cytotoxicity to endothelial and smooth muscle cells, inhibition of endothelial cell-dependent arterial relaxation, and reduced motility of macrophages. 21, 22) In this study, the total cholesterol and LDL cholesterol levels in group II patients were higher than in group I patients, however, the difference was not significant. We expect that these results may be related to the patients who had high cholesterol levels and received lipid lowering agents and/or diet therapy.
The routine administration of intravenous iron preparations, as a means for anemia correction in most HD patients, has been shown to improve both survival and quality of life. 23, 24) Iron saccarate is considered a safe and efficacious preparation. 25, 26) However, parenteral iron overload has been linked with tissue deposition of iron, and potentially can increase oxidative stress, thereby inducing cardiac disease. 7) Drueke, et al found that C-IMT and the carotid wall-to-lumen ratio were associated with plasma advanced oxidation protein products, serum ferritin, and annual intravenous iron dose administered. 16) Prospective results from the Bruneck study in humans provided strong evidence for a role of iron status in coronary heart disease. 27) In contrast, an analysis of prospective studies in nonuremic populations did not provide good evidence of a strong association between iron status and coronary heart disease. 28) In the present study, we found that there is a significant relationship between C-IMT, ferritin, and the cumulative dose of intravenous iron given to treat anemia. In patients given IV iron therapy, C-IMT was higher than in patients who were not.
In conclusion, the findings indicate that IV iron therapy and elevated serum ferritin levels may cause an increase in the incidence of atherosclerosis. We acknowledge that to confirm these preliminary results and to firmly establish the relationship between supplemental iron administration, excess iron, and cardiac disease, large prospective studies are needed.
